High and variable population prevalence of HLA‐B*56:02 in indigenous Australians and relation to phenytoin‐associated drug reaction with eosinophilia and systemic symptoms

A.A. Somogyi; D.T. Barratt; E.J. Phillips; K. Moore; F. Ilyas; G.M. Gabb

doi:10.1111/bcp.14025

Back

High and variable population prevalence of HLA‐B*56:02 in indigenous Australians and relation to phenytoin‐associated drug reaction with eosinophilia and systemic symptoms

Journal article

Peer reviewed

High and variable population prevalence of HLA‐B*56:02 in indigenous Australians and relation to phenytoin‐associated drug reaction with eosinophilia and systemic symptoms

A.A. Somogyi, D.T. Barratt, E.J. Phillips, K. Moore, F. Ilyas and G.M. Gabb

British Journal of Clinical Pharmacology, Early View

2019

DOI: https://doi.org/10.1111/bcp.14025

Files and links (1)

url

Link to Published Version *Subscription may be requiredView

Abstract

Phenytoin drug reaction with eosinophilia and systemic symptoms (DRESS) in 3 Aboriginal Australians positive for HLA‐B*56:02 has been previously reported. We report the allele frequency of HLA‐B*56:02 in 2 South Australian populations, 1 Aboriginal (4.8%, 95% confidence interval 2.4–7.8%) and the other European (0%). We compared the frequency with publicly available information on HLA‐B*56:02 status in other Indigenous Australian (n = 4) and European Australian cohorts (n = 1). In the Indigenous Australian cohorts, HLA‐B*56:02 allele frequency ranged from 1.3 to 19%. We also describe an additional case of phenytoin DRESS (RegiSCAR DRESS score 7) in an Aboriginal Australian that was associated with HLA‐B*56:02 and with CYP2C9*1/*3 genotype. In Aboriginal Australians, phenytoin DRESS appears distinctly linked to HLA‐B*56:02 with an allele carriage rate substantially higher than in Europeans, but also with considerable regional variation. Investigations of human leucocyte antigen and other contributing genes and severe adverse drug reactions in understudied non‐European populations are required to optimize safe medication use and inform risk mitigation strategies.

Details

Title: High and variable population prevalence of HLA‐B*56:02 in indigenous Australians and relation to phenytoin‐associated drug reaction with eosinophilia and systemic symptoms
Authors/Creators: A.A. Somogyi (Author/Creator) - Royal Adelaide Hospital
D.T. Barratt (Author/Creator) - The University of Adelaide
E.J. Phillips (Author/Creator) - Vanderbilt University
K. Moore (Author/Creator) - Royal Adelaide Hospital
F. Ilyas (Author/Creator) - Royal Adelaide Hospital
G.M. Gabb (Author/Creator) - The University of Adelaide
Publication Details: British Journal of Clinical Pharmacology, Early View
Publisher: Wiley
Identifiers: 991005542555407891
Copyright: © 2019 The British Pharmacological Society
Murdoch Affiliation: Institute for Immunology and Infectious Diseases
Language: English
Resource Type: Journal article

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Metrics

79 Record Views

19 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.265 Dermatology - Skin Allergies; 1.265.1140 Drug Hypersensitivity
Web Of Science research areas: Pharmacology & Pharmacy
ESI research areas: Pharmacology & Toxicology